TY  - JOUR
AU  - Kühn, Michael W M
AU  - Pemmaraju, Naveen
AU  - Heidel, Florian H
TI  - The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.
JO  - Leukemia
VL  - 39
IS  - 8
SN  - 0887-6924
CY  - London
PB  - Springer Nature
M1  - DKFZ-2025-01017
SP  - 1824-1837
PY  - 2025
N1  - 39(8):1824-1837
AB  - Research on myeloid neoplasms, a field that has been driving scientific advances in cancer for over 50 years, has yielded many discoveries that have fundamentally reshaped our understanding of cancer biology. These insights, often the product of leukemia research, have been instrumental in developing more mechanism-based treatments in the early 2000s [1]. Recognizing epigenetic dysregulation as a common disease mechanism in myeloid cancers has been groundbreaking regarding recent treatment developments that exploit chromatin-based oncogenic mechanisms. In the case of acute myeloid leukemia (AML), sequencing studies aimed at assessing the complement of genetic alterations demonstrated that more than 60
LB  - PUB:(DE-HGF)16
C6  - pmid:40374809
DO  - DOI:10.1038/s41375-025-02639-x
UR  - https://inrepo02.dkfz.de/record/301475
ER  -